<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834206</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-NDP-SGL arm</org_study_id>
    <nct_id>NCT04834206</nct_id>
  </id_info>
  <brief_title>Nedaplatin in Treatment for Nasopharyngeal Carcinoma</brief_title>
  <official_title>Induction Chemotherapy With Nedaplatin, Docetaxel and 5-Fluorouracil Followed by Concurrent Nedaplatin and Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Single Arm, Open Label, Multicenter, Phase II Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of induction chemotherapy with nedaplatin, docetaxel and&#xD;
      5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in&#xD;
      locally advanced nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase II clinical trial to evaluate the efficacy and safety of&#xD;
      induction chemotherapy with nedaplatin, docetaxel and 5-Fluorouracil followed by concurrent&#xD;
      nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma&#xD;
      patients. This is a multicenter study. All patients will be enrolled in endemic area. All&#xD;
      patients will receive radical intense modulate radiation therapy (IMRT). The primary endpoint&#xD;
      is objective response rate (ORR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>at the end of radiotherapy(±1week）</time_frame>
    <description>CR+PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The OS was defined as the duration from the date of beginning of treatment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progress-free survival is calculated from the date of beginning of treatment to the date of locoregional failure, distant failure, or death from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival(LRRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Relapse-free survival was defined as the time from beginning of treatment to local or regional relapse, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-Free Survival(DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Distant metastasis-free survival was defined as the time from beginning of treatment to distant metastasis, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire module for head and neck (EORTC QLQ-H&amp;N35). The EORTC QLQ-H&amp;N35 scale employs a 4-point response format (&quot;not at all&quot; to &quot;very much&quot;). Scale scores are transformed to a scale from 0 to 100 according to the EORTC scoring algorithm. For the functioning and the global QoL scale, a higher score indicates better health. For the symptom scales, a higher score indicates a higher level of symptom burden. Either English or Chinese version will be used according to patient's language habits.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>DNF-N</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction chemotherapy:&#xD;
three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks&#xD;
Concurrent chemoradiotherapy:&#xD;
three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy&#xD;
Radiotherapy: radical intense modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, nedaplatin, fluorouracil</intervention_name>
    <description>Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.</description>
    <arm_group_label>DNF-N</arm_group_label>
    <other_name>DNF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.</description>
    <arm_group_label>DNF-N</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.</description>
    <arm_group_label>DNF-N</arm_group_label>
    <other_name>N</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly histologically confirmed non-keratinizing nasopharyngeal&#xD;
             carcinoma, including WHO II or III&#xD;
&#xD;
          -  Original clinical staged as III-IVa (except T3-4N0) according to the 8th edition&#xD;
             American Joint Committee on Cancer staging system&#xD;
&#xD;
          -  No evidence of distant metastasis (M0)&#xD;
&#xD;
          -  Age between 18-65&#xD;
&#xD;
          -  WBC≥4×10^9/ l, platelet ≥ 100×10^9/ l and hemoglobin ≥ 90g/l&#xD;
&#xD;
          -  With normal liver function test (TBIL、ALT、AST ≤ 2.5×uln)&#xD;
&#xD;
          -  With normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml/min)&#xD;
&#xD;
          -  Satisfactory performance status: KARNOFSKY scale (KPS) &gt; 70&#xD;
&#xD;
          -  Patients must give signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with palliative intent&#xD;
&#xD;
          -  The primary tumor or lymph node has undergone chemotherapy or surgery (except&#xD;
             operations for diagnostic purposes)&#xD;
&#xD;
          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical cancer&#xD;
&#xD;
          -  History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the&#xD;
             primary tumor or nodes&#xD;
&#xD;
          -  History of previous radiotherapy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             acute exacerbation of chronic obstructive pulmonary disease or other respiratory&#xD;
             illness requiring admission to hospital, active hepatitis, and mental disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinquan Liu, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinquan Liu, M.D</last_name>
    <phone>0086-137-1086-6485</phone>
    <email>609149209@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Qi, M.D</last_name>
    <phone>0086-135-8058-0985</phone>
    <email>qibin020@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of radiotherapy(Section 5),Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical Universityedical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinquan Liu, M.D</last_name>
      <phone>0086-137-1086-6485</phone>
      <email>609149209@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Bin Qi, M.D</last_name>
      <phone>0086-135-8058-0985</phone>
      <email>qibin020@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jinquan Liu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Qi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jin-Quan Liu</investigator_full_name>
    <investigator_title>Section Chief</investigator_title>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Nedaplatin</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

